Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway

Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies

(2020) Marina N. Sharifi et al.   CANCER

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

(2020) Michela Piezzo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.

(2019) Baptiste Louveau et al.   JOURNAL OF CLINICAL ONCOLOGY

Post-Translational Modifications of the Mini-Chromosome Maintenance Proteins in DNA Replication

(2019) Li et al.   Genes

LNK suppresses interferon signaling in melanoma

(2019) Ling-Wen Ding et al.   Nature Communications

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

(2019) Jiayi Yu et al.   CLINICAL CANCER RESEARCH

MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway

(2019) Yemei Yang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Cyclin-dependent kinase activity is required for type I interferon production

(2018) Oya Cingöz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma

(2018) Jennie W. Taylor et al.   JOURNAL OF NEURO-ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2015) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

Cell cycle control as a promising target in melanoma

(2015) Belinda Lee et al.   CURRENT OPINION IN ONCOLOGY

Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker

(2014) Johanne Lade-Keller et al.   JOURNAL OF CLINICAL PATHOLOGY

Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling

(2014) Miriam Potrony et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

(2014) V. Yadav et al.   MOLECULAR CANCER THERAPEUTICS

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Hypoxia. Cross talk between oxygen sensing and the cell cycle machinery

(2011) Gregg L. Semenza   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

(2011) Zhihong Chi et al.   BMC CANCER

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

(2011) Lu Si et al.   EUROPEAN JOURNAL OF CANCER

Acral Lentiginous Melanoma

(2009) Porcia T. Bradford et al.   ARCHIVES OF DERMATOLOGY